| Abstrakt: |
Doxorubicin is a key treatment for breast cancer, but its effectiveness often comes with significant side effects. Its actions include DNA intercalation, topoisomerase II inhibition, and reactive oxygen species generation, leading to DNA damage and cell death. However, it can also cause heart problems and low blood cell counts. Current trials aim to improve doxorubicin therapy by adjusting doses, using different administration methods, and combining it with targeted treatments or immunotherapy. Nanoformulations show promise in enhancing doxorubicin's effectiveness by improving drug delivery, reducing side effects, and overcoming drug resistance. This review summarizes recent progress and difficulties in using doxorubicin for breast cancer, highlighting its mechanisms, side effects, ongoing trials, and the potential impact of nanoformulations. Understanding these different aspects is crucial in optimizing doxorubicin's use and improving outcomes for breast cancer patients. This review examines the toxicity of doxorubicin, a drug used in breast cancer treatment, and discusses strategies to mitigate adverse effects, such as cardioprotective agents and liposomal formulations. It also discusses clinical trials evaluating doxorubicin-based regimens, the evolving landscape of combination therapies, and the potential of nanoformulations to optimize delivery and reduce systemic toxicity. The review also discusses the potential of liposomes, nanoparticles, and polymeric micelles to enhance drug accumulation within tumor tissues while sparing healthy organs. Representation of the role of Doxorubicin in cancer therapy, highlighting its utilization across diverse nano-formulations and combined strategies aimed at augmenting targeted delivery to tumor cells. Through intricate nano-engineering, these formulations enhance the specificity of Doxorubicin, ensuring its preferential accumulation within cancerous tissues while mitigating systemic toxicity to healthy cells. By harnessing the principles of targeted drug delivery, these approaches seek to amplify the therapeutic efficacy of Doxorubicin, inducing programmed cell death specifically within malignant cells, and thereby minimizing collateral damage to surrounding healthy tissues. [ABSTRACT FROM AUTHOR] |
Full text from SpringerLink